STING1 and neoplasm: It has been demonstrated that STING agonists have promising biological activity and show excellent synergistic anti-tumor effects in combination with other cancer therapies such as radiotherapy, chemotherapy, or immune therapies, as proven in preclinical studies and some clinical trials.